GlucoTrack, Inc. (NASDAQ:GCTK – Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 16,200 shares, a growth of 36.1% from the August 15th total of 11,900 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is currently 1.1 days. Currently, 0.6% of the shares of the stock are short sold.
GlucoTrack Price Performance
NASDAQ:GCTK traded down $0.05 during trading hours on Monday, hitting $2.86. The company’s stock had a trading volume of 10,870 shares, compared to its average volume of 28,136. The stock has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.13. The company has a market capitalization of $15.67 million, a P/E ratio of -1.41 and a beta of 0.13. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.12 and a quick ratio of 0.12. GlucoTrack has a twelve month low of $0.66 and a twelve month high of $4.95.
GlucoTrack (NASDAQ:GCTK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.82) earnings per share for the quarter.
About GlucoTrack
GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.
Featured Stories
- Five stocks we like better than GlucoTrack
- Which Wall Street Analysts are the Most Accurate?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Start Investing in Real Estate
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.